Tuesday, October 20, 2015 3:04:17 PM
To begin with, there is no exact science to picking stocks that could double. In other words, understand that any stocks mentioned here could actually lose value. Nonetheless, if you're looking for a high-risk but potentially high-reward company that could possibly double in 2016, I'd suggest digging deeper into clinical-stage vaccine developer Inovio Pharmaceuticals (NASDAQ:INO).
Inovio is a bifurcated vaccine developer, meaning that half of its pipeline is devoted to infectious disease vaccine development, such as hepatitis B & C, as well as ebola and influenza, while the remainder of its pipeline is working on the development of cancer immunotherapies, which enhance the body's ability to fight cancer by reducing its immunosuppressant quality. If you're curious about which aspect is most important, Inovio's management is clear that oncology research takes precedence.
I believe the two big catalysts in 2016 could be a combination of collaborative deals and the expectation of potentially positive clinical data.
Inovio's lead drug is VGX-3100, a DNA-based immunotherapy that hit its primary endpoint in cervical dysplasia caused by human papillomavirus types 16 or 18. Aside from kicking off its phase 3 study in 2016, shareholders may get data on INO-1400, a phase 1 study in breast, lung, and pancreatic cancer, INO-3106 for aerodigestive cancer caused by HPV type 6, and interim data from its all-important study of INO-3112 for head and neck cancer as well as cervical cancer. INO-3112 is licensed out to MedImmune, meaning Inovio's advancement of INO-3112 could net the company some much-welcomed cash.
Additionally, Inovio has landed Roche and MedImmune as collaborative partners within the past two years. As Inovio's vaccine development program continues to demonstrate promise, it's possible it could attract more partners. I'm not going to speculate who those partners might be, but the cancer immunotherapy space is so hot right now that companies like Inovio with more than a half-dozen ongoing cancer studies are likely on a lot of larger pharmaceutical companies' radars.
Down around 35% year-to-date, I believe Inovio could be a good candidate for a catalyst-driven rebound in 2016.
http://www.fool.com/investing/general/2015/10/20/5-stocks-that-could-double-in-2016.aspx
Recent INO News
- INOVIO to Present at Upcoming Scientific Conference • PR Newswire (US) • 09/17/2024 08:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/13/2024 10:22:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:06:54 AM
- INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 • PR Newswire (US) • 07/25/2024 08:05:00 PM
- INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 • PR Newswire (US) • 07/25/2024 12:00:00 PM
- INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway • PR Newswire (US) • 07/11/2024 12:00:00 PM
- INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer • PR Newswire (US) • 07/02/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 07/01/2024 08:00:00 PM
- INOVIO Added to Russell 2000® Index Effective July 1, 2024 • PR Newswire (US) • 07/01/2024 12:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc. • PR Newswire (US) • 06/04/2024 12:00:00 PM
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/31/2024 08:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:49:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:13:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:11:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:10:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM